{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T11:36:33Z","timestamp":1794742593048,"version":"4.9.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    JNJ-54175446 is a selective purine P2X7 receptor (P2X7R) antagonist that attenuates microglial IL-1\u03b2\/IL-18 release. In healthy volunteers, JNJ-54175446 suppressed peripheral interleukin (IL)-1\u03b2 release, and attenuated dexamphetamine-induced improvements of mood and (visuo)motor performance in a human dexamphetamine-challenge paradigm. In depression, P2X7R inhibition may dampen immune-related dysregulation of mood. These results suggest that the impact of P2X7R inhibition is most prominent in situations where mood regulation is disrupted. Total sleep deprivation (TSD) results in an acute emotional perturbation, which yields a transient antidepressant effect. In the current study, TSD was applied as a behavioral challenge to investigate whether such effects could be modulated by JNJ-54175446. This was a double-blind, placebo-controlled, randomized study to assess the safety and pharmacokinetics of JNJ-54175446 and explore its effects in patients with single episode and recurrent major depressive disorder (MDD) (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200969) and baseline total Inventory of Depressive Symptomatology Clinician Rated (IDS-C)\u2009&gt;\u200930. Patients were randomized to receive JNJ-54175446 throughout the 10-day treatment period, placebo for days 1\u20133 followed by JNJ-54175446 or placebo throughout. All patients underwent 36\u2009h of TSD starting on day three until the evening of day four. The early start group was hypothesized to experience a reduced effect from TSD whilst the late starting group was hypothesized to experience prolonged effects from the TSD. JNJ-54175446 was well-tolerated and adverse events were mild to moderate. JNJ-54175446 reduced IL-1\u03b2 release by LPS-stimulated peripheral white blood cells in the presence of the P2X receptor agonist benzyl adenosine triphosphate (BzATP). JNJ-54175446 did not have a significant effect on mood as assessed using the Hamilton Depression Rating Scale, 17 items (HDRS17) and the Self-rated Quick Inventory of Depressive Symptoms (QIDS-SR). However, JNJ-54175446 blunted an acute reduction of anhedonia that occurred as a result of TSD, assessed by the Snaith-Hamilton Pleasure Scale (SHAPS) and the Probabilistic Instrumental Learning Task (PILT).\n                  <\/jats:p>","DOI":"10.1038\/s41398-023-02557-5","type":"journal-article","created":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T22:01:36Z","timestamp":1690149696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9282-9307","authenticated-orcid":false,"given":"Kasper","family":"Recourt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Ark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Benes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop M. A.","family":"van Gerven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ceusters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"van Nueten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne C.","family":"Drevets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindya","family":"Bhatacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Browning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel E.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"2557_CR1","doi-asserted-by":"crossref","unstructured":"Sluyter R. The P2X7 receptor. In: Protein Reviews. Springer; Vol 19 2017. p. 17\u201353.","DOI":"10.1007\/5584_2017_59"},{"key":"2557_CR2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/bph.12314","volume":"170","author":"A Bhattacharya","year":"2013","unstructured":"Bhattacharya A, Wang Q, Ao H, Shoblock JR, Lord B, Aluisio L, et al. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ\u201047965567. Br J Pharm. 2013;170:624\u201340.","journal-title":"Br J Pharm"},{"key":"2557_CR3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1023\/A:1012388618693","volume":"26","author":"P Bodin","year":"2001","unstructured":"Bodin P, Burnstock G. Purinergic signalling: ATP release. Neurochem Res. 2001;26:959\u201369.","journal-title":"Neurochem Res"},{"key":"2557_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0028-3908(97)00140-8","volume":"36","author":"G Collo","year":"1997","unstructured":"Collo G, Neidhart S, Kawashima E, Kosco-Vilbois M, North RA, Buell G. Tissue distribution of the P2X7 receptor. Neuropharmacology. 1997;36:1277\u201383.","journal-title":"Neuropharmacology"},{"key":"2557_CR5","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1096\/fj.11-196089","volume":"26","author":"T Engel","year":"2012","unstructured":"Engel T, Gomez-Villafuertes R, Tanaka K, Mesuret G, Sanz-Rodriguez A, Garcia-Huerta P, et al. Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J. 2012;26:1616\u201328.","journal-title":"FASEB J"},{"key":"2557_CR6","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.4049\/jimmunol.176.7.3877","volume":"176","author":"D Ferrari","year":"2006","unstructured":"Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol. 2006;176:3877\u201383.","journal-title":"J Immunol"},{"key":"2557_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1034\/j.1600-0447.2001.00162.x","volume":"103","author":"BM Owen","year":"2001","unstructured":"Owen BM, Eccleston D, Ferrier IN, Young H. Raised levels of plasma interleukin\u20101\u03b2 in major and postviral depression. Acta Psychiatr Scand. 2001;103:226\u20138.","journal-title":"Acta Psychiatr Scand"},{"key":"2557_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/13543776.2017.1246538","volume":"27","author":"J-H Park","year":"2017","unstructured":"Park J-H, Kim Y-C. P2X7 receptor antagonists: a patent review (2010\u20132015). Expert Opin Ther Pat. 2017;27:257\u201367.","journal-title":"Expert Opin Ther Pat"},{"key":"2557_CR9","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1523\/JNEUROSCI.1469-04.2004","volume":"24","author":"JA Sim","year":"2004","unstructured":"Sim JA, Young MT, Sung H-Y, North RA, Surprenant A. Reanalysis of P2X7 receptor expression in rodent brain. J Neurosci. 2004;24:6307\u201314.","journal-title":"J Neurosci"},{"key":"2557_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1503\/jpn.100080","volume":"36","author":"J S\u00f6derlund","year":"2011","unstructured":"S\u00f6derlund J, Olsson SK, Samuelsson M, Walther-Jallow L, Johansson C, Erhardt S, et al. Elevation of cerebrospinal fluid interleukin-1\u03b2 in bipolar disorder. J Psychiatry Neurosci. 2011;36:114.","journal-title":"J Psychiatry Neurosci"},{"key":"2557_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/00048670701399994","volume":"41","author":"MR Bennett","year":"2007","unstructured":"Bennett MR. Synaptic P2X7 receptor regenerative-loop hypothesis for depression. Aust NZ J Psychiatry. 2007;41:563\u201371.","journal-title":"Aust NZ J Psychiatry"},{"key":"2557_CR12","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.2174\/138920111798357429","volume":"12","author":"A Bhattacharya","year":"2011","unstructured":"Bhattacharya A, Neff RA, Wickenden AD. The physiology, pharmacology and future of P2X7 as an analgesic drug target: hype or promise? Curr Pharm Biotechnol. 2011;12:1698\u2013706.","journal-title":"Curr Pharm Biotechnol"},{"key":"2557_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbi.2012.12.008","volume":"31","author":"M Iwata","year":"2013","unstructured":"Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun. 2013;31:105\u201314.","journal-title":"Brain Behav Immun"},{"key":"2557_CR14","first-page":"231","volume":"14","author":"B Sperlagh","year":"2012","unstructured":"Sperlagh B, Csolle C, Ando RD, Goloncser F, Kittel A, Baranyi M. The role of purinergic signaling in depressive disorders. Neuropsychopharmacol Hung. 2012;14:231\u20138.","journal-title":"Neuropsychopharmacol Hung"},{"key":"2557_CR15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fncel.2015.00258","volume":"9","author":"L Stokes","year":"2015","unstructured":"Stokes L, Spencer SJ, Jenkins TA. Understanding the role of P2X7 in affective disorders\u2014are glial cells the major players? Front Cell Neurosci. 2015;9:258.","journal-title":"Front Cell Neurosci"},{"key":"2557_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/mp.2017.188","volume":"23","author":"A Cheffer","year":"2018","unstructured":"Cheffer A, Castillo ARG, Corr\u00eaa-Velloso J, Gon\u00e7alves MCB, Naaldijk Y, Nascimento IC, et al. Purinergic system in psychiatric diseases. Mol Psychiatry. 2018;23:94.","journal-title":"Mol Psychiatry"},{"key":"2557_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Y Dowlati","year":"2010","unstructured":"Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446\u201357.","journal-title":"Biol Psychiatry"},{"key":"2557_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/npp.2011.205","volume":"37","author":"E Haroon","year":"2012","unstructured":"Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012;37:137.","journal-title":"Neuropsychopharmacology"},{"key":"2557_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","volume":"71","author":"MB Howren","year":"2009","unstructured":"Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171\u201386.","journal-title":"Psychosom Med"},{"key":"2557_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2008.01.004","volume":"85","author":"H Anisman","year":"2008","unstructured":"Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol. 2008;85:1\u201374.","journal-title":"Prog Neurobiol"},{"key":"2557_CR21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1124\/pr.113.008144","volume":"66","author":"AK Walker","year":"2014","unstructured":"Walker AK, Kavelaars A, Heijnen CJ, Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharm Rev. 2014;66:80\u2013101.","journal-title":"Pharm Rev"},{"key":"2557_CR22","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/mp.2016.3","volume":"21","author":"DR Goldsmith","year":"2016","unstructured":"Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21:1696.","journal-title":"Mol Psychiatry"},{"key":"2557_CR23","first-page":"4195","volume":"55","author":"CA K\u00f6hler","year":"2018","unstructured":"K\u00f6hler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol. 2018;55:4195\u2013206.","journal-title":"Mol Neurobiol"},{"key":"2557_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.neuron.2018.08.001","volume":"99","author":"SA Syed","year":"2018","unstructured":"Syed SA, Beurel E, Loewenstein DA, Lowell JA, Craighead WE, Dunlop BW, et al. Defective inflammatory pathways in never-treated depressed patients are associated with poor treatment response. Neuron. 2018;99:914\u2013924. e3.","journal-title":"Neuron"},{"key":"2557_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jad.2014.12.015","volume":"174","author":"Z Ayorech","year":"2015","unstructured":"Ayorech Z, Tracy DK, Baumeister D, Giaroli G. Taking the fuel out of the fire: evidence for the use of anti-inflammatory agents in the treatment of bipolar disorders. J Affect Disord. 2015;174:467\u201378.","journal-title":"J Affect Disord"},{"key":"2557_CR26","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1001\/jamapsychiatry.2014.1611","volume":"71","author":"O K\u00f6hler","year":"2014","unstructured":"K\u00f6hler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71:1381\u201391.","journal-title":"JAMA Psychiatry"},{"key":"2557_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.biopsych.2015.11.026","volume":"80","author":"M Iwata","year":"2016","unstructured":"Iwata M, Ota KT, Li X-Y, Sakaue F, Li N, Dutheil S, et al. Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2X7 receptor. Biol Psychiatry. 2016;80:12\u201322.","journal-title":"Biol Psychiatry"},{"key":"2557_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fphar.2018.00030","volume":"9","author":"A Bhattacharya","year":"2018","unstructured":"Bhattacharya A. Recent advances in CNS P2X7 physiology and pharmacology: focus on neuropsychiatric disorders. Front Pharm. 2018;9:30.","journal-title":"Front Pharm"},{"key":"2557_CR29","doi-asserted-by":"publisher","first-page":"e66547","DOI":"10.1371\/journal.pone.0066547","volume":"8","author":"C Cs\u00f6lle","year":"2013","unstructured":"Cs\u00f6lle C, Baranyi M, Zsilla G, Kittel \u00c1, G\u00f6l\u00f6ncs\u00e9r F, Illes P, et al. Neurochemical changes in the mouse hippocampus underlying the antidepressant effect of genetic deletion of P2X7 receptors. PLoS ONE. 2013;8:e66547.","journal-title":"PLoS ONE"},{"key":"2557_CR30","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.bbi.2010.06.001","volume":"24","author":"Y-X Chu","year":"2010","unstructured":"Chu Y-X, Zhang Y, Zhang Y-Q, Zhao Z-Q. Involvement of microglial P2X7 receptors and downstream signaling pathways in long-term potentiation of spinal nociceptive responses. Brain Behav Immun. 2010;24:1176\u201389.","journal-title":"Brain Behav Immun"},{"key":"2557_CR31","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1021\/acs.jmedchem.7b01279","volume":"61","author":"CC Chrovian","year":"2017","unstructured":"Chrovian CC, Soyode-Johnson A, Peterson AA, Gelin CF, Deng X, Dvorak CA, et al. A dipolar cycloaddition reaction to access 6-methyl-4, 5, 6, 7-tetrahydro-1 H-[1\u20133] triazolo [4, 5-c] pyridines enables the discovery synthesis and preclinical profiling of a P2X7 antagonist clinical candidate. J Med Chem. 2017;61:207\u201323.","journal-title":"J Med Chem"},{"key":"2557_CR32","unstructured":"Letavic MA, Savall BM, Allison BD, Aluisio L, Andres JI, De Angelis M, et al. 4-Methyl-6, 7-dihydro-4 H-triazolo [4, 5-c] pyridine-Based P2X7 receptor antagonists: optimization of pharmacokinetic properties leading to the identification of a clinical candidate. 2017;4559\u201372."},{"key":"2557_CR33","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1016\/j.bmcl.2016.06.048","volume":"26","author":"JC Rech","year":"2016","unstructured":"Rech JC, Bhattacharya A, Letavic MA, Savall BM. The evolution of P2X7 antagonists with a focus on CNS indications. Bioorg Med Chem Lett. 2016;26:3838\u201345.","journal-title":"Bioorg Med Chem Lett"},{"key":"2557_CR34","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1124\/jpet.114.218487","volume":"351","author":"B Lord","year":"2014","unstructured":"Lord B, Aluisio L, Shoblock JR, Neff RA, Varlinskaya EI, Ceusters M, et al. Pharmacology of a novel central nervous system\u2013penetrant P2X7 antagonist JNJ-42253432. J Pharmacol Exp Ther. 2014;351:628\u201341.","journal-title":"J Pharmacol Exp Ther"},{"key":"2557_CR35","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s12035-014-9031-z","volume":"53","author":"C Gubert","year":"2016","unstructured":"Gubert C, Fries GR, Pfaffenseller B, Ferrari P, Coutinho-Silva R, Morrone FB, et al. Role of P2X7 receptor in an animal model of mania induced by D-amphetamine. Mol Neurobiol. 2016;53:611\u201320.","journal-title":"Mol Neurobiol"},{"key":"2557_CR36","doi-asserted-by":"publisher","first-page":"e6006","DOI":"10.1371\/journal.pone.0006006","volume":"4","author":"VF Labrousse","year":"2009","unstructured":"Labrousse VF, Costes L, Aubert A, Darnaud\u00e9ry M, Ferreira G, Am\u00e9d\u00e9e T, et al. Impaired interleukin-1\u03b2 and c-Fos expression in the hippocampus is associated with a spatial memory deficit in P2X7 receptor-deficient mice. PLoS ONE. 2009;4:e6006.","journal-title":"PLoS ONE"},{"key":"2557_CR37","doi-asserted-by":"publisher","unstructured":"Boucher AA, Arnold JC, Hunt GE, Spiro A, Spencer J, Brown C, et al. Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test. Neuroscience 2011;189. https:\/\/doi.org\/10.1016\/j.neuroscience.2011.05.049.","DOI":"10.1016\/j.neuroscience.2011.05.049"},{"key":"2557_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1017\/S1461145711001933","volume":"16","author":"C Cs\u00f6lle","year":"2013","unstructured":"Cs\u00f6lle C, And\u00f3 RD, Kittel A, G\u00f6l\u00f6ncs\u00e9r F, Baranyi M, Soproni K, et al. The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice. Int J Neuropsychopharmacol. 2013;16:213\u201333.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2557_CR39","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1177\/0269881118800067","volume":"32","author":"M Timmers","year":"2018","unstructured":"Timmers M, Ravenstijn P, Xi L, Triana-Baltzer G, Furey M, Van Hemelryck S, et al. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants. J Psychopharmacol. 2018;32:1341\u201350.","journal-title":"J Psychopharmacol"},{"key":"2557_CR40","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1177\/0269881120914206","volume":"34","author":"K Recourt","year":"2020","unstructured":"Recourt K, van der Aart J, Jacobs G, de Kam M, Drevets W, van Nueten L, et al. Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. J Psychopharmacol. 2020;34:1030\u201342.","journal-title":"J Psychopharmacol"},{"key":"2557_CR41","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/j.1365-2125.2012.04200.x","volume":"74","author":"SM McHugh","year":"2012","unstructured":"McHugh SM, Roman S, Davis B, Koch A, Pickett AM, Richardson JC, et al. Effects of genetic variation in the P2RX7 gene on pharmacodynamics of a P2X7 receptor antagonist: a prospective genotyping approach. Br J Clin Pharm. 2012;74:376\u201380.","journal-title":"Br J Clin Pharm"},{"key":"2557_CR42","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.5664\/JCSM.1360","volume":"7","author":"JM Clinton","year":"2011","unstructured":"Clinton JM, Davis CJ, Zielinski MR, Jewett KA, Krueger JM. Biochemical regulation of sleep and sleep biomarkers. J Clin Sleep Med. 2011;7:S38\u2013S42.","journal-title":"J Clin Sleep Med"},{"key":"2557_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0165-1781(00)00164-5","volume":"95","author":"C Colombo","year":"2000","unstructured":"Colombo C, Lucca A, Benedetti F, Barbini B, Campori E, Smeraldi E. Total sleep deprivation combined with lithium and light therapy in the treatment of bipolar depression: replication of main effects and interaction. Psychiatry Res. 2000;95:43\u201353.","journal-title":"Psychiatry Res"},{"key":"2557_CR44","doi-asserted-by":"publisher","first-page":"e4589","DOI":"10.1371\/journal.pone.0004589","volume":"4","author":"WMA van Leeuwen","year":"2009","unstructured":"van Leeuwen WMA, Lehto M, Karisola P, Lindholm H, Luukkonen R, Sallinen M, et al. Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PLoS ONE. 2009;4:e4589.","journal-title":"PLoS ONE"},{"key":"2557_CR45","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1007\/s00018-015-2044-6","volume":"72","author":"D Chaudhury","year":"2015","unstructured":"Chaudhury D, Liu H, Han M-H. Neuronal correlates of depression. Cell Mol Life Sci. 2015;72:4825\u201348.","journal-title":"Cell Mol Life Sci"},{"key":"2557_CR46","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1586\/ern.11.61","volume":"11","author":"S Dallaspezia","year":"2011","unstructured":"Dallaspezia S, Benedetti F. Chronobiological therapy for mood disorders. Expert Rev Neurother. 2011;11:961\u201370.","journal-title":"Expert Rev Neurother"},{"key":"2557_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1053\/smrv.2002.0235","volume":"6","author":"H Giedke","year":"2002","unstructured":"Giedke H, Schw\u00e4rzler F. Therapeutic use of sleep deprivation in depression. Sleep Med Rev. 2002;6:361\u201377.","journal-title":"Sleep Med Rev"},{"key":"2557_CR48","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiatry. 2006;163:1905\u201317.","journal-title":"Am J Psychiatry"},{"key":"2557_CR49","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1176\/ajp.147.1.14","volume":"147","author":"JC Wu","year":"1990","unstructured":"Wu JC, Bunney WE. The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis. Am J Psychiatry. 1990;147:14\u201321.","journal-title":"Am J Psychiatry"},{"key":"2557_CR50","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00004714-199906000-00007","volume":"19","author":"F Benedetti","year":"1999","unstructured":"Benedetti F, Colombo C, Barbini B, Campori E, Smeraldi E. Ongoing lithium treatment prevents relapse after total sleep deprivation. J Clin Psychopharmacol. 1999;19:240\u20135.","journal-title":"J Clin Psychopharmacol"},{"key":"2557_CR51","first-page":"893.","volume":"78.8","author":"EM Boland","year":"2017","unstructured":"Boland EM, Rao H, Dinges DF, Smith RV, Goel N, Detre JA, et al. Meta-Analysis of the Antidepressant Effects of Acute Sleep Deprivation. J Clin Psychiatry. 2017;78.8:893.","journal-title":"J Clin Psychiatry"},{"key":"2557_CR52","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/(SICI)1520-6394(1997)6:3<113::AID-DA4>3.0.CO;2-E","volume":"6","author":"GM Bump","year":"1997","unstructured":"Bump GM, Reynolds CF III, Smith G, Pollock BG, Dew MA, Mazumdar S, et al. Accelerating response in geriatric depression: a pilot study combining sleep deprivation and paroxetine. Depress Anxiety. 1997;6:113\u20138.","journal-title":"Depress Anxiety"},{"key":"2557_CR53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jad.2005.04.008","volume":"88","author":"O Caliyurt","year":"2005","unstructured":"Caliyurt O, Guducu F. Partial sleep deprivation therapy combined with sertraline induces more rapid improvements in quality of life items in major depressive disorder. J Affect Disord. 2005;88:75\u20138.","journal-title":"J Affect Disord"},{"key":"2557_CR54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0165-0327(95)00074-7","volume":"37","author":"H Kuhs","year":"1996","unstructured":"Kuhs H, F\u00e4rber D, Borgst\u00e4dt S, Mrosek S, T\u00f6lle R. Amitriptyline in combination with repeated late sleep deprivation versus amitriptyline alone in major depression. A randomised study. J Affect Disord. 1996;37:31\u201341.","journal-title":"J Affect Disord"},{"key":"2557_CR55","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1176\/ajp.156.5.683","volume":"156","author":"GS Smith","year":"1999","unstructured":"Smith GS, Reynolds CF III, Pollock B, Derbyshire S, Nofzinger E, Dew MA, et al. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. Am J Psychiatry. 1999;156:683\u20139.","journal-title":"Am J Psychiatry"},{"key":"2557_CR56","doi-asserted-by":"publisher","first-page":"343.","DOI":"10.1038\/s41398-019-0671-7","volume":"9.1","author":"JC Foo","year":"2019","unstructured":"Foo JC, Trautmann N, Sticht C, Treutlein J, Frank J, Streit F, et al. Longitudinal transcriptome-wide gene expression analysis of sleep deprivation treatment shows involvement of circadian genes and immune pathways. Transl Psychiatry. 2019;9.1:343.","journal-title":"Transl Psychiatry"},{"key":"2557_CR57","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.bbi.2007.04.003","volume":"21","author":"DJ Frey","year":"2007","unstructured":"Frey DJ, Fleshner M, Wright KP Jr. The effects of 40\u2009h of total sleep deprivation on inflammatory markers in healthy young adults. Brain Behav Immun. 2007;21:1050\u20137.","journal-title":"Brain Behav Immun"},{"key":"2557_CR58","doi-asserted-by":"publisher","unstructured":"Kurczewska E, Ferensztajn-Rochowiak E, Jasi\u0144ska-Miko\u0142ajczyk A, Ch\u0142opocka-Wo\u017aniak M, Rybakowski JK. Augmentation of Pharmacotherapy by Sleep Deprivation with Sleep Phase Advance in Treatment-Resistant Depression. Pharmacopsychiatry 2019;52. https:\/\/doi.org\/10.1055\/a-0695-9138.","DOI":"10.1055\/a-0695-9138"},{"key":"2557_CR59","doi-asserted-by":"crossref","unstructured":"Posner K, Brent D, Lucas C, Gould M, Stanley B, Brown G, et al. Columbia-suicide severity rating scale (C-SSRS). New York, NY: Columbia University Medical Center; 2008.","DOI":"10.1037\/t52667-000"},{"key":"2557_CR60","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1017\/S0033291703001107","volume":"34","author":"MH Trivedi","year":"2004","unstructured":"Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34:73\u201382.","journal-title":"Psychol Med"},{"key":"2557_CR61","doi-asserted-by":"publisher","first-page":"80.","DOI":"10.1037\/1040-3590.7.1.80","volume":"7.1","author":"SL Curran","year":"1995","unstructured":"Curran SL, Andrykowski MA, Studts JL. Short form of the profile of mood states (POMS-SF): psychometric information. Psychol assess. 1995;7.1:80.","journal-title":"Psychol assess"},{"key":"2557_CR62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1192\/bjp.167.1.99","volume":"167","author":"RP Snaith","year":"1995","unstructured":"Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith\u2013Hamilton Pleasure Scale. Br J Psychiatry. 1995;167:99\u2013103.","journal-title":"Br J Psychiatry"},{"key":"2557_CR63","doi-asserted-by":"publisher","first-page":"482.","DOI":"10.3389\/fpsyt.2018.00482","volume":"9","author":"A Walsh","year":"2018","unstructured":"Walsh A, Brown R, Browning M, Cowen P, Harmer C, Huneke N. A Double Blind Randomised Trial to Investigate the Acute Effects of the Dopaminergic Antidepressant Bupropion on Emotional and Reward Processing in Healthy Volunteers. Front Psychiatry. 2018;9:482.","journal-title":"Front Psychiatry"},{"key":"2557_CR64","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.brainresbull.2009.06.016","volume":"80","author":"Y Gorgulu","year":"2009","unstructured":"Gorgulu Y, Caliyurt O. Rapid antidepressant effects of sleep deprivation therapy correlates with serum BDNF changes in major depression. Brain Res Bull. 2009;80:158\u201362.","journal-title":"Brain Res Bull"},{"key":"2557_CR65","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.4088\/JCP.v66n1207","volume":"66","author":"F Benedetti","year":"2005","unstructured":"Benedetti F, Barbini B, Fulgosi MC, Colombo C, Dallaspezia S, Pontiggia A, et al. Combined total sleep deprivation and light therapy in the treatment of drug-resistant bipolar depression: acute response and long-term remission rates. J Clin Psychiatry. 2005;66:1535\u201340.","journal-title":"J Clin Psychiatry"},{"key":"2557_CR66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/0006-3223(95)00086-0","volume":"39","author":"A Neumeister","year":"1996","unstructured":"Neumeister A, Goessler R, Lucht M, Kapitany T, Bamas C, Kasper S. Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. Biol Psychiatry. 1996;39:16\u201321.","journal-title":"Biol Psychiatry"},{"key":"2557_CR67","unstructured":"Pharmaceuticals J A Randomised, Placebo-controlled, Double-blind Trial of the Antidepressant Efficacy of a Novel CNS-penetrant P2X7 Receptor Antagonist, JNJ-54175446, in People With Major Depressive Disorder, an Incomplete Response to Monoaminergic Antidepressant Drugs, and a Biomarker Profile Predictive of Active P2X7 Signalling. Clinicaltrials.gov, 2019 https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04116606."},{"key":"2557_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","volume":"70","author":"CL Raison","year":"2013","unstructured":"Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31\u201341.","journal-title":"JAMA Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02557-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02557-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02557-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T23:11:29Z","timestamp":1690153889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02557-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2557"],"URL":"https:\/\/doi.org\/10.1038\/s41398-023-02557-5","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"6 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The current study was funded by Janssen Research and Development. KR MD, Dr GJ and Prof Dr JvG declare no competing interests. Dr PdB, Dr PvdA, Dr HB, Dr MC, Dr AB, Dr LvN and Prof Dr WD are employees of Janssen and own Johnson and Johnson equity. Dr MB is employed by the University of Oxford and has acted as a consultant for Jansen Research and CHDR.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"266"}}